Key result
The ixCELL-DCM trial is an ongoing phase 2b study designed to assess the efficacy and safety of transendocardial injection of ixmyelocel-T versus placebo in 114 patients with heart failure due to IDCM.
Why the study?
Does catheter-based transendocardial injection of ixmyelocel-T reduce deaths, cardiovascular hospitalizations, or unplanned clinic visits in patients with symptomatic heart failure due to ischemic dilated cardiomyopathy?
RCT (n=114)
Double-blind
1:1 ratio
Does catheter-based transendocardial injection of ixmyelocel-T reduce deaths, cardiovascular hospitalizations, or unplanned clinic visits in patients with symptomatic heart failure due to ischemic dilated cardiomyopathy?
The ixCELL-DCM trial is designed to evaluate the efficacy and safety of transendocardial injection of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Reduces events in advanced ischemic HFrEF; extends cell therapy data to the largest RCT in this population.
Henry et al. (2016) conducted an RCT in Ischemic dilated cardiomyopathy (IDCM) with heart failure (n=114). ixmyelocel-T vs. Placebo (vehicle control) was evaluated on Composite of the total number of deaths, cardiovascular hospitalizations, or unplanned clinic visits to treat acutely decompensated heart failure. The ixCELL-DCM trial is an ongoing phase 2b study designed to assess the efficacy and safety of transendocardial injection of ixmyelocel-T versus placebo in 114 patients with heart failure due to IDCM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: